Efficacy News and Research

RSS

Novel method can improve the detection of circulating tumor cells

Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80 percent of all lung cancer cases.

10 Mar 2021

Study provides accurate data on allergic reactions related to mRNA COVID-19 vaccines

Almost immediately after the first mRNA-based COVID-19 vaccines were authorized for emergency use and were administered to individuals outside of clinical trials, reports of anaphylaxis--a life-threatening whole-body allergic reaction--raised widespread concerns among experts and the public.

10 Mar 2021

New SARS-CoV-2 vaccine candidate produces strong immune response, prevents SARS-CoV-2 infection

A new SARS-CoV-2 vaccine candidate, developed by giving a key protein's gene a ride into the body while encased in a measles vaccine, has been shown to produce a strong immune response and prevent SARS-CoV-2 infection and lung disease in multiple animal studies.

10 Mar 2021

FDA qualifies C-Path’s DIBSS-C for clinical trials

Critical Path Institute's (C-Path) Patient-Reported Outcome (PRO) Consortium announces the qualification of the Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C) by the U.S. Food and Drug Administration (FDA).

10 Mar 2021

Delaying second doses of COVID-19 vaccines has benefits, but longer-term results rely on robust immunity

Delaying second doses of COVID-19 vaccines should reduce case numbers in the near term.

10 Mar 2021

Researchers discover new COVID-19 variants in three South African provinces

Variants of the coronavirus are appearing in different parts of the world, many of them spreading with alarming speed.

10 Mar 2021

PRRT technology may offer new treatment approaches for neuroendocrine tumors

Neuroendocrine tumors are cancers that begin in specialized cells called neuroendocrine cells. These cells have traits similar to those of nerve cells and hormone-producing cells.

9 Mar 2021

Vaccine mRNA not found in breast milk after COVID mRNA vaccination

A study conducted by researchers in the United States has found no evidence to suggest that the messenger RNA (mRNA) present in the Pfizer-BioNTech and Moderna vaccines that protect against coronavirus disease 2019 (COVID-19) can be transferred to human breast milk.

9 Mar 2021

Project Helios launched to unlock new approaches in small molecule drug discovery

The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions.

9 Mar 2021

Five herbal medicines show potent activity against Babesia duncani in the lab

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced the publication of new data finding that five herbal medicines had potent activity compared to commonly-used antibiotics in test tubes against Babesia duncani, a malaria-like parasite found on the West Coast of the U.S. that causes the disease babesiosis.

9 Mar 2021

Phase 2 clinical trial is now open at Columbia to test gene therapy for dry macular degeneration

A phase 2 clinical trial is underway at Columbia University and NewYork-Presbyterian to test an investigational gene therapy for dry age-related macular degeneration, a progressive, chronic eye disease with no cure and a leading cause of blindness in the United States.

9 Mar 2021

Translational research results in promising combination therapeutic candidate for type 1 diabetes

Translational research led by scientists at La Jolla Institute for Immunology (LJI) has resulted in a promising combination therapeutic candidate for adults with recent-onset type 1 diabetes.

9 Mar 2021

Computerized, remote training program alleviates negative emotions in preadolescents

Anxiety levels in the United States are rising sharply and have especially intensified in younger populations.

9 Mar 2021

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

A new study, released as a preprint on the bioRxiv* server, reports an optimized coronavirus disease 2019 (COVID-19) vaccine candidate, which, claim the researchers, may be less likely to produce reactions like fevers. It may also have increased protective potential against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes COVID-19.

9 Mar 2021

Ultraviolet light therapy reduces viral load in critically ill COVID-19 patients

Scientists from the United States has recently evaluated the safety and efficacy profiles of ultraviolet-A (UVA) light applied via an endotracheal tube to critically ill COVID-19 patients.

9 Mar 2021

Parkinson’s UK, University of Sheffield to develop new Parkinson’s drug

Parkinson's UK, the largest charitable funder of Parkinson's research in Europe, is investing up to £1.2 million into a pioneering one-year project in partnership with the University of Sheffield.

9 Mar 2021

Transmission risk for schistosomiasis peaks at higher water temperature

About one billion people worldwide are at risk for schistosomiasis -- a debilitating disease caused by parasitic worms that live in fresh water and in intermediate snail hosts.

9 Mar 2021

Current vaccines and therapies may be less effective at neutralizing new SARS-CoV-2 variants

A new study of the U.K. and South Africa variants of SARS-CoV-2 predicts that current vaccines and certain monoclonal antibodies may be less effective at neutralizing these variants and that the new variants raise the specter that reinfections could be more likely.

8 Mar 2021

Worse problems with SARS-CoV-2 variants may be on the way

Researchers at the Department of Integrative Biomedical Sciences, University of Cape Town, South Africa, found evidence of a significant change in the selective forces acting on immunologically important SARS-CoV-2 genes, such as N and S. These likely coincided with the emergence of the 501Y lineages.

8 Mar 2021

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

The currently developed vaccines against SARS-CoV-2 include the RBD in their immunogen. With a similar objective, a new study developed an RBD protein-based vaccine candidate against the SARS-CoV-2, using self-assembling Helicobacter pylori-bullfrog ferritin nanoparticles as an antigen delivery system. The study is published recently in the journal mBio (by the American Society of Microbiology).

8 Mar 2021

Efficacy News and Research

Novel method can improve the detection of circulating tumor cells

Study provides accurate data on allergic reactions related to mRNA COVID-19 vaccines

New SARS-CoV-2 vaccine candidate produces strong immune response, prevents SARS-CoV-2 infection

FDA qualifies C-Path’s DIBSS-C for clinical trials

Delaying second doses of COVID-19 vaccines has benefits, but longer-term results rely on robust immunity

Researchers discover new COVID-19 variants in three South African provinces

PRRT technology may offer new treatment approaches for neuroendocrine tumors

Vaccine mRNA not found in breast milk after COVID mRNA vaccination

Project Helios launched to unlock new approaches in small molecule drug discovery

Five herbal medicines show potent activity against Babesia duncani in the lab

Phase 2 clinical trial is now open at Columbia to test gene therapy for dry macular degeneration

Translational research results in promising combination therapeutic candidate for type 1 diabetes

Computerized, remote training program alleviates negative emotions in preadolescents

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

Ultraviolet light therapy reduces viral load in critically ill COVID-19 patients

Parkinson’s UK, University of Sheffield to develop new Parkinson’s drug

Transmission risk for schistosomiasis peaks at higher water temperature

Current vaccines and therapies may be less effective at neutralizing new SARS-CoV-2 variants

Worse problems with SARS-CoV-2 variants may be on the way

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News